Study of KU-2285 with Intraoperative Radiotherapy
Author Information
Author(s): Y Shibamoto, G Ohshio, R Hosotani, Y Nishimura, T Manabe, M Imamura, M Abel
Primary Institution: Kyoto University
Hypothesis
Does the hypoxic cell radiosensitizer KU-2285 improve outcomes when combined with intraoperative radiotherapy (IORT) for patients with unresectable tumors?
Conclusion
The study found that KU-2285 combined with IORT showed encouraging results in terms of survival and local control for patients with unresectable pancreatic cancer.
Supporting Evidence
- Patients treated with KU-2285 had a median survival time of 11 months compared to 8 months for historical controls.
- The 1-year local control rate for patients receiving KU-2285 was 50%, compared to 28% for controls.
- No drug-related toxicity was observed in any patients.
Takeaway
Doctors tested a new drug called KU-2285 to see if it helps patients with hard-to-treat tumors when used with special radiation therapy, and it seemed to work well.
Methodology
Patients with unresectable tumors received KU-2285 before IORT, and their outcomes were compared to historical controls.
Limitations
The study had a small sample size and was not a formal phase I trial.
Participant Demographics
30 patients, 21 males and 9 females, median age 59 years, with 23 having pancreatic cancer and 5 having osteosarcoma.
Statistical Information
P-Value
0.26 for survival, 0.10 for local control
Statistical Significance
p=0.26 for survival, p=0.10 for local control
Want to read the original?
Access the complete publication on the publisher's website